Healthcare
Tengion, Inc.(TNGNQ)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+900.00%
Window
Jun 23, 2025 → Jun 18, 2026
- Market Cap
- —
- Revenue Growth
- 0.0%
- EPS Growth
- +21.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tengion, Inc. (TNGNQ) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 900.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +21.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +21.2%, free cash flow +11.5% with operating margin 0.0% and ROIC -159.4%. Stock Foundry combines TNGNQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +21.2%, while operating margin sits near 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TNGNQ
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TNGNQ Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TNGNQ and SPY.
Company Overview
Tengion, Inc.
Other OTC
Tengion, Inc. operates as a regenerative medicine company. The company focuses on discovering, developing, manufacturing, and commercializing a range of neo-organs or products composed of living cells with or without synthetic or natural materials that are implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. Its product portfolio includes Neo-Kidney Augment to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease; and Neo-Urinary Conduit, which is in Phase I clinical trial and used to replace the use of bowel tissue in bladder cancer patients requiring a non-continent urinary diversion after bladder removal surgery. The company has a license agreement with Children's Medical Center Corporation (CMCC) for the license of certain patent rights and intellectual property rights owned or controlled by CMCC related to tissue engineering technology. Tengion, Inc. was founded in 2003 and is headquartered in Winston-Salem, North Carolina. On December 29, 2014, Tengion, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
- Leadership
- David I. Scheer
- IPO Date
- Nov 23, 2022
- Employees
- 25
- Street Address
- 3929 Westpoint Boulevard
- Mailing
- Winston-Salem
- Region
- Winston-Salem, US
- Reporting Currency
- USD
- Investor Line
- +1 336 722 5559
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- —
Growth
- Revenue
- 0.0%
- EPS
- +21.2%
- Free Cash Flow
- +11.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 188.3%
- ROIC
- -159.4%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 1.31
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.